Survival Benefit of Intravenous Busulfan (120 Mg/M2) and Fludarabine Myeloablative Regimen for Treatment of Myeloid Malignancies
Journal of Stem Cell Research & Therapy
doi 10.4172/2157-7633.1000338
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2016
Authors
Publisher
OMICS Publishing Group